See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Baidu, Inc. (BIDU) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baidu, Inc. (BIDU) - free report >>
Image: Bigstock
New Strong Sell Stocks for July 20th
Here are five stocks added to the Zacks Rank #5 (Strong Sell) List today:
Aeva Technologies, Inc. (AEVA - Free Report) is building the next-generation of sensing and perception for autonomous vehicles and beyond. The Zacks Consensus Estimate for its current year earnings has been revised 2.8% downward over the last 30 days.
Baidu, Inc. (BIDU - Free Report) provides internet search services. The Zacks Consensus Estimate for its current year earnings has been revised 4.2% downward over the last 30 days.
CymaBay Therapeutics, Inc. is a biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 0.9% downward over the last 30 days.
Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The Zacks Consensus Estimate for its current year earnings has been revised 5.7% downward over the last 30 days.
Ferrari N.V. (RACE - Free Report) is engaged in designing, manufacturing and selling sports cars. The Zacks Consensus Estimate for its current year earnings has been revised 4.3% downward over the last 30 days.
View the entire Zacks Rank #5 List.